Skip to main content
OpenTrials
Completed

NCT Number: NCT06647238

Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperlipidemia Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Dyslipidemias Heart Diseases Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Myocardial Ischemia Nutritional and Metabolic Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atrium Health Cabarrus

Concord, North Carolina, 28025, United States

About this study

Studies have shown prevention of cardiovascular adverse events is directly proportional to percent reduction in low-density lipoprotein (LDL). This evidence explains why LDL targets for secondary prevention have continued to be lowered. Cholesterol guidelines have been updated recently and encourage the use of multiple lipid lowering therapies, in addition to statins, for secondary prevention. However, these novel agents can be expensive and difficult to acquire, making prescribing challenging for providers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of coronary artery disease
  • low-density lipoprotein (LDL) > 55
  • Primary Care Physician at 1 of 6 identified clinics

Exclusion criteria

  • Patients who are no longer an active patient of one of the internal medicine practices
  • Patients whose cholesterol is managed by another practice
  • Women of childbearing age/potential
  • Patients residing in hospice/Long Term Care facilities
  • End-stage liver disease

Treatment and study plan

Pharmacist Intervention in lipid therapy

Other

Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.

Primary outcomes

  1. Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55)

    Time frame: Month 5

    patients with LDL within goal (<55) (yes/no)

Secondary outcomes

  1. Percent Change in Low-density Lipoprotein (LDL)

    Time frame: Baseline to end of study period up to Month 5

    Percent LDL reduction (will use baseline LDL and lowest LDL)

  2. Number of Participants With Medications Initiated or Titrated

    Time frame: Baseline to end of study period up to Month 5

    Number of Medications initiated or titrated

  3. Prevalence of Elevated Lipoprotein(a)

    Time frame: Baseline to end of study period up to Month 5

    Number of Subjects with Prevalence of elevated Lipoprotein(a)

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Registry information

Official study title

Second Time's the Charm: Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 17, 2024
Registry last updated
Jul 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.